[{"abstract": "If a merger with Pfizer really makes sense, AstraZeneca\u2019s decision is not now or never, Christopher Hughes of Reuters Breakingviews writes.", "web_url": "https://dealbook.nytimes.com/2014/05/21/a-giant-drug-deal-first-needs-a-rest-and-then-a-fresh-start/", "snippet": "If a merger with Pfizer really makes sense, AstraZeneca\u2019s decision is not now or never, Christopher Hughes of Reuters Breakingviews writes.", "lead_paragraph": "AstraZeneca should not re-engage with Pfizer in the dying days of the takeover timetable. Talks now would either be fruitless or delay a proper restart later.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg", "height": 900, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 900}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-jumbo.jpg", "height": 1024, "width": 683, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-superJumbo.jpg", "height": 2048, "width": 1366, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer-AstraZeneca Talks Need a Rest and Then a Fresh Start", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}, {"name": "glocations", "value": "Great Britain", "rank": 5, "major": "N"}], "pub_date": "2014-05-21T16:18:13+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Christopher Hughes", "person": [{"firstname": "Christopher", "middlename": null, "lastname": "Hughes", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/3c2d92e0-83b8-5332-883d-4fd27cf6d7ab", "word_count": 519, "uri": "nyt://article/3c2d92e0-83b8-5332-883d-4fd27cf6d7ab"}, {"abstract": "The fragmented response offers a glimmer of hope to Pfizer, but AstraZeneca also contends that under British takeover law, its hands are tied unless a third part steps in with a competing bid.", "web_url": "https://dealbook.nytimes.com/2014/05/21/astrazenecas-shareholders-remain-sharply-divided-over-talks-with-pfizer/", "snippet": "The fragmented response offers a glimmer of hope to Pfizer, but AstraZeneca also contends that under British takeover law, its hands are tied unless a third part steps in with a competing bid.", "lead_paragraph": "LONDON \u2013 AstraZeneca\u2019s decision not to pursue merger talks with Pfizer\u00a0 has caused a split among the British-Swedish drug maker\u2019s shareholders, \u00a0with several large shareholders publicly and privately voicing opposing views on Wednesday on the potential tie-up.", "print_section": "B", "print_page": "4", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/22/business/dbpix-drug1/dbpix-drug1-articleLarge.jpg", "height": 366, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/22/business/dbpix-drug1/dbpix-drug1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 366}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/22/business/dbpix-drug1/dbpix-drug1-jumbo.jpg", "height": 625, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/22/business/dbpix-drug1/dbpix-drug1-superJumbo.jpg", "height": 1250, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "AstraZeneca\u2019s Shareholders Remain Sharply Divided Over Talks With Pfizer", "kicker": "DealBook", "content_kicker": null, "print_headline": "Shareholders Divided", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Axa SA", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 5, "major": "N"}], "pub_date": "2014-05-21T17:42:54+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Chad Bray", "person": [{"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/4e0d2234-1084-5b9f-bc10-6e74820978f1", "word_count": 607, "uri": "nyt://article/4e0d2234-1084-5b9f-bc10-6e74820978f1"}]